Literature DB >> 8030246

Identification of a vaccinia virus penetration protein.

Y Ichihashi1, T Takahashi, M Oie.   

Abstract

A vaccinia virus structural protein responsible for infection was identified by monoclonal antibodies (mAb). Two mAbs (2D5 and 8C2) neutralized the virus at a dilution of about 10(5). The 2D5 mAb reacted with VP29K under standard immunoblotting conditions and with a 23-kDa protein when virus was dissociated under nonreducing conditions. The 8C2 mAb reacted with the 23-kDa protein, but not with VP29K. Two-dimensional electrophoresis demonstrated that the 23-kDa protein was the nonreduced form of VP29K. Since they possess the same N-terminal amino acid sequence, the protein was renamed VP23-29K. The gene that encoded it was HindIII A17L ORF. The VP23-29K-dependent process of infection did not occur during the adsorption phase at 4 degrees, and trypsin-treated virus could complete the process within 10 min at 37 degrees. One half of the trypsin-treated intracellular mature virus (IMV) achieved the process within 20 min, but for normal IMV this time period was 2 hr. VP23-29K had function for the early step of penetration, and the functional site in the nonreduced 23-kDa form was masked to some extent in normal virus. The late cell fusion by the fusion positive (F+) D1 mutant proceeded in neutral pH. Cells infected with F- IHD-J strain virus did not fuse, but a short treatment with pH 5 medium developed cell fusion. Both of the cell fusions were inhibited by the 2D5 and 8C2 mAbs. Virion VP23-29K was suggested to be the fusion protein for the early penetration and the late cell fusion phases of vaccinia infection cycle.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8030246     DOI: 10.1006/viro.1994.1405

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  20 in total

1.  Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus.

Authors:  M I Vázquez; M Esteban
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo.

Authors:  C L Lin; C S Chung; H G Heine; W Chang
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein.

Authors:  Hua-Poo Su; Joseph W Golden; Apostolos G Gittis; Jay W Hooper; David N Garboczi
Journal:  Virology       Date:  2007-08-03       Impact factor: 3.616

4.  T cell antigen discovery using soluble vaccinia proteome reveals recognition of antigens with both virion and nonvirion association.

Authors:  D Huw Davies; Sookhee Chun; Gary Hermanson; Jo Anne Tucker; Aarti Jain; Rie Nakajima; Jozelyn Pablo; Philip L Felgner; Xiaowu Liang
Journal:  J Immunol       Date:  2014-07-14       Impact factor: 5.422

5.  Vaccinia virus penetration requires cholesterol and results in specific viral envelope proteins associated with lipid rafts.

Authors:  Che-Sheng Chung; Cheng-Yen Huang; Wen Chang
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.

Authors:  D Huw Davies; Megan M McCausland; Conrad Valdez; Devan Huynh; Jenny E Hernandez; Yunxiang Mu; Siddiqua Hirst; Luis Villarreal; Philip L Felgner; Shane Crotty
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entry.

Authors:  Chwan Hong Foo; J Charles Whitbeck; Manuel Ponce-de-León; Wan Ting Saw; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

8.  Acidic residues in the membrane-proximal stalk region of vaccinia virus protein B5 are required for glycosaminoglycan-mediated disruption of the extracellular enveloped virus outer membrane.

Authors:  Kim L Roberts; Adrien Breiman; Gemma C Carter; Helen A Ewles; Michael Hollinshead; Mansun Law; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

9.  Determinant in human immunodeficiency virus type 1 for efficient replication under cytokine-induced CD4(+) T-helper 1 (Th1)- and Th2-type conditions.

Authors:  Y Suzuki; Y Koyanagi; Y Tanaka; T Murakami; N Misawa; N Maeda; T Kimura; H Shida; J A Hoxie; W A O'Brien; N Yamamoto
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  Early viral protein synthesis is necessary for NF-kappaB activation in modified vaccinia Ankara (MVA)-infected 293 T fibroblast cells.

Authors:  Stefani Martin; Joanna L Shisler
Journal:  Virology       Date:  2009-06-18       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.